<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60918">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02312882</url>
  </required_header>
  <id_info>
    <org_study_id>31790ORO</org_study_id>
    <nct_id>NCT02312882</nct_id>
  </id_info>
  <brief_title>Tofacitinib for the Treatment of Alopecia Areata and Its Variants</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus
      kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia
      areata and its variants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label pilot study. Participants will be treated with oral tofacitinib
      for 3 months. Participants will be evaluated for 6 months after completion of therapy to
      evaluate for durability of response, late response and/or late adverse effects.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Severity of Alopecia Tool (SALT) Score</measure>
    <time_frame>0 and 3 months</time_frame>
    <description>SALT score range is from 0 (no hair loss) to 100 (100% hair loss)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Alopecia Areata</condition>
  <condition>Alopecia Totalis</condition>
  <condition>Alopecia Universalis</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tofacitinib administration</intervention_name>
    <description>5 mg of tofacitinib will be taken by mouth twice a day for three months.</description>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;= 18 years old

          -  Diagnosis of alopecia areata with &gt;50% scalp involvement, alopecia totalis, or
             alopecia universalis

          -  Hair loss present for at least 6 months

          -  No treatment for alopecia areata in past 2 months

          -  No evidence of hair regrowth

          -  Females of childbearing potential must use birth control while taking the medication
             and there must be a negative pregnancy test documented prior to starting the
             medication

          -  Fluent in spoken and written English

        Exclusion Criteria:

          -  Age &lt;18 years old

          -  Patients have received treatment known to affect alopecia areata within 2 months of
             enrolling in the study

          -  Patients with a history of malignancy (except history of successfully treated basal
             cell or squamous cell carcinoma of the skin)

          -  Patients known to be HIV or hepatitis B or C positive

          -  Patients with positive tuberculin skin test or positive QuantiFERON TB test

          -  Patients with leukopenia or anemia

          -  Patients with renal or hepatic impairment

          -  Patients with peptic ulcer disease

          -  Patients taking immunosuppressive medications, including but not limited to
             prednisone, methotrexate, mycophenolate mofetil, azathioprine, tacrolimus,
             cyclosporine, or TNH-alpha inhibitors

          -  Women of childbearing potential who are unable or unwilling to use birth control
             while taking the medication

          -  Women who are pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 7, 2016</lastchanged_date>
  <firstreceived_date>December 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Anthony Oro</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
